Novo Nordisk Shares Face Critical Test Amid Institutional Exodus

Danish pharmaceutical leader Novo Nordisk is confronting a severe market downturn as major investors rapidly divest their holdings. The company’s stock has plummeted 58% from its peak levels and now approaches a crucial support threshold that could determine its near-term trajectory. This selling pressure follows management’s decision to significantly scale back annual performance expectations.

Revised Outlook Sparks Concern

The core issue driving the selloff stems from disappointing operational developments. Novo Nordisk has substantially lowered its full-year 2025 guidance, now projecting revenue growth of just 8-11% at constant exchange rates, markedly below previous expectations.

Market analysts point to slowing momentum for the company’s flagship medications Wegovy and Ozempic as the primary concern. These former growth drivers now face intensified competitive pressure and pricing challenges. The company’s third-quarter performance already showed signs of strain, with revenues of $11.74 billion slightly missing analyst projections. Although earnings per share of $1.02 exceeded expectations, this positive detail has been overwhelmingly overshadowed by the reduced forward-looking guidance.

Major Investors Execute Strategic Retreat

Institutional confidence appears to be eroding rapidly, with several prominent financial firms substantially reducing their exposure:

Should investors sell immediately? Or is it worth buying Novo Nordisk?

• Rockefeller Capital Management liquidated 37.3% of its position, selling 245,379 shares
• Thoroughbred Financial Services slashed its holdings by a dramatic 72.5%
• Rothschild Investment divested 87.2% of its stake, totaling 105,363 shares

This coordinated retreat by financial heavyweights signals profound concern about the company’s near-term recovery prospects. The additional selling pressure compounds existing downward momentum in the share price.

Contrarian Signals Emerge

Amid the widespread pessimism, some countervailing signals have emerged. Board member Stephan Engels demonstrated confidence by acquiring 6,450 B-shares on November 17. While insider purchases often indicate long-term conviction, this gesture appears minimal compared to the institutional outflow volume.

Short sellers have shown relative restraint despite the sharp decline, with only 0.6-0.8% of freely tradable shares currently held in short positions. This suggests speculative investors aren’t aggressively betting on further substantial losses.

The equity now tests critical support around $48. Market participants await clarity on whether this level will stabilize the decline or whether additional downward movement lies ahead for the Wegovy manufacturer.